CFTR and cystic fibrosis: In order to monitor CFTR activity based on the effect of the only VX770, we selected a group of CF patients, carrying residual function (Supplementary Materials Table S1: CFTR mutations of the CF patients eligible for Ivacaftor therapy) and eligible for Ivacaftor therapy, before and after the ex vivo cell treatment with VX770.